Is BIOVF or JEPQ a better dividend investment in 2026?

BIOVF currently yields 5.02% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: JEPQ offers higher current income.

What is the dividend yield difference between BIOVF and JEPQ?

BIOVF has a forward dividend yield of 5.02% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 6.08 percentage points.

Home › Compare › BIOVF vs JEPQ

BIOVF vs JEPQ: Dividend Comparison 2026

BIOVF yields 5.02% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 JEPQ wins by $17.0K in total portfolio value

INVESTMENT

TIME HORIZON10 years

BIOVF

● Live price

5.02%

Share price

$39.87

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27.8K

Annual income

$691.40

Full BIOVF calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — BIOVF vs JEPQ

📍 JEPQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BIOVF	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BIOVF + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BIOVF pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOVF

Annual income on $10K today (after 15% tax)

$426.38/yr

After 10yr DRIP, annual income (after tax)

$587.69/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, JEPQ beats the other by $1,242.01/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOVF + JEPQ for your $10,000?

BIOVF: 50%JEPQ: 50%

100% JEPQ50/50100% BIOVF

Portfolio after 10yr

$36.3K

Annual income

$1,421.99/yr

Blended yield

3.92%

📊

Analyst Conviction Gap

Where Wall Street is split right now

BIOVF

Analyst Ratings

Hold

Consensus: Hold

Altman Z

3.7

Piotroski

6/9

JEPQ

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOVF buys

JEPQ buys

No recent congressional trades found for BIOVF or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBIOVFJEPQ

Forward yield	5.02%	11.10% ✓
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$27.8K	$44.8K ✓
Annual income after 10y	$691.40	$2,152.59 ✓
Total dividends collected	$6.0K	$16.3K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: BIOVF vs JEPQ ($10,000, DRIP)

Year	BIOVF Portfolio	BIOVF Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$11,202	$501.63	$11,930	$1,110.39	$728.00 → JEPQ
2	$12,511	$525.15	$14,133	$1,224.34	$1.6K → JEPQ
3	$13,935	$548.15	$16,632	$1,340.46	$2.7K → JEPQ
4	$15,481	$570.60	$19,454	$1,457.97	$4.0K → JEPQ
5	$17,157	$592.44	$22,626	$1,576.08	$5.5K → JEPQ
6	$18,972	$613.63	$26,175	$1,694.09	$7.2K → JEPQ
7	$20,934	$634.14	$30,133	$1,811.32	$9.2K → JEPQ
8	$23,053	$653.95	$34,531	$1,927.17	$11.5K → JEPQ
9	$25,340	$673.04	$39,403	$2,041.08	$14.1K → JEPQ
10	$27,805	$691.40	$44,787	$2,152.59	$17.0K → JEPQ

BIOVF vs JEPQ: Complete Analysis 2026

BIOVF — Stock

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Full BIOVF Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this BIOVF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOVF vs SCHD BIOVF vs JEPI BIOVF vs O BIOVF vs KO BIOVF vs MAIN BIOVF vs XYLD BIOVF vs QYLD BIOVF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.